Article: Efficacy of Combination Chemotherapy with Irinotecan (CPT-11) plus Capecitabine in Patients with Metastatic or Advanced Colorectal Carcinoma - a Dual-centre Phase II Study: the MAC-6

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleEfficacy of Combination Chemotherapy with Irinotecan (CPT-11) plus Capecitabine in Patients with Metastatic or Advanced Colorectal Carcinoma - a Dual-centre Phase II Study: the MAC-6
AuthorsChoi, CKK2
Chan, RTT2
Tung, SY1
Lui, L2
Siu, S2
Au, GKH2
Ho, JWC2
Law, WL2
KeywordsCapecitabine
CPT-11
irinotecan
metastatic colorectal cancer
Issue Date2008
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/clon
CitationClinical Oncology, 2008, v. 20 n. 2, p. 168-175 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.clon.2007.11.008
AbstractAims: A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer. Patients and methods: Patients received a combination of CPT-11 plus capecitabine. CPT-11 was infused intravenously on day 1 every 2 weeks and oral capecitabine was taken twice daily for 5 days every 7 days. Efficacy and toxicities were assessed. Results: Between 2004 and 2005, 43 patients were enrolled. The overall response rate was 51.35%. With a median follow-up of 13 months, the median time to progression was 10 months (95% confidence interval 7.6-12.3 months); the median survival was 15 months (95% confidence interval 13.9-16.9 months). The most common grade 3 haematological and non-haematological toxicities were neutropenia (5.4%), diarrhoea (8.1%) and hand-foot syndrome (2.7%). Conclusions: CPT-11 plus capecitabine with a 14 day cycle showed a comparable response with international phase II data with a 3 weekly regimen and was well tolerated as a first-line palliative chemotherapy in patients with metastatic colorectal cancer. The data should be interpreted with caution due to the limited sample size and should be further confirmed by a phase III randomised trial. © 2007 The Royal College of Radiologists.
ISSN0936-6555
2011 Impact Factor: 2.072
2011 SCImago Journal Rankings: 0.198
DOIhttp://dx.doi.org/10.1016/j.clon.2007.11.008
ISI Accession Number IDWOS:000254160500009
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorChoi, CKK
dc.contributor.authorChan, RTT
dc.contributor.authorTung, SY
dc.contributor.authorLui, L
dc.contributor.authorSiu, S
dc.contributor.authorAu, GKH
dc.contributor.authorHo, JWC
dc.contributor.authorLaw, WL
dc.date.accessioned2010-09-06T08:42:01Z
dc.date.available2010-09-06T08:42:01Z
dc.date.issued2008
dc.description.abstractAims: A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer. Patients and methods: Patients received a combination of CPT-11 plus capecitabine. CPT-11 was infused intravenously on day 1 every 2 weeks and oral capecitabine was taken twice daily for 5 days every 7 days. Efficacy and toxicities were assessed. Results: Between 2004 and 2005, 43 patients were enrolled. The overall response rate was 51.35%. With a median follow-up of 13 months, the median time to progression was 10 months (95% confidence interval 7.6-12.3 months); the median survival was 15 months (95% confidence interval 13.9-16.9 months). The most common grade 3 haematological and non-haematological toxicities were neutropenia (5.4%), diarrhoea (8.1%) and hand-foot syndrome (2.7%). Conclusions: CPT-11 plus capecitabine with a 14 day cycle showed a comparable response with international phase II data with a 3 weekly regimen and was well tolerated as a first-line palliative chemotherapy in patients with metastatic colorectal cancer. The data should be interpreted with caution due to the limited sample size and should be further confirmed by a phase III randomised trial. © 2007 The Royal College of Radiologists.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationClinical Oncology, 2008, v. 20 n. 2, p. 168-175 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.clon.2007.11.008
dc.identifier.doihttp://dx.doi.org/10.1016/j.clon.2007.11.008
dc.identifier.epage175
dc.identifier.hkuros141229
dc.identifier.isiWOS:000254160500009
dc.identifier.issn0936-6555
2011 Impact Factor: 2.072
2011 SCImago Journal Rankings: 0.198
dc.identifier.issue2
dc.identifier.openurl
dc.identifier.pmid18155454
dc.identifier.scopuseid_2-s2.0-39049165189
dc.identifier.spage168
dc.identifier.urihttp://hdl.handle.net/10722/83520
dc.identifier.volume20
dc.languageeng
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/clon
dc.publisher.placeUnited Kingdom
dc.relation.ispartofClinical Oncology
dc.relation.referencesReferences in Scopus
dc.subjectCapecitabine
dc.subjectCPT-11
dc.subjectirinotecan
dc.subjectmetastatic colorectal cancer
dc.titleEfficacy of Combination Chemotherapy with Irinotecan (CPT-11) plus Capecitabine in Patients with Metastatic or Advanced Colorectal Carcinoma - a Dual-centre Phase II Study: the MAC-6
dc.typeArticle
Author Affiliations
  1. Tuen Mun Hospital
  2. Queen Mary Hospital Hong Kong